billHR10904•Event Thursday, October 22, 2026Analyzed

To direct the Federal Trade Commission to convene an interagency working group to track and report on market concentration and monopoly activity with respect to certain sectors of the economy, and for other purposes.

Neutral

Summary

HR10904 directs the FTC to convene an interagency working group to track and report on market concentration and monopoly activity. The bill is in early stage, referred to the House Judiciary Committee, with no cosponsors. As a study-only bill with no direct regulatory or funding mechanism, its near-term market impact is negligible.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.No direct market impact from this study-only bill
  • 2.Early legislative stage with low momentum (no cosponsors, junior sponsor)
  • 3.No funding or regulatory teeth; purely informational

Market Implications

No immediate implications for any publicly traded company. The bill does not alter any company's revenue, costs, or competitive landscape. Investors should monitor for future antitrust enforcement actions separately, but this bill itself is not a market-moving event.

Full Analysis

HR10904 was introduced in the House on 2026-10-22 by Rep. Vindman (D-VA) and referred to the House Committee on the Judiciary. The bill directs the Federal Trade Commission to convene an interagency working group to track and report on market concentration and monopoly activity in certain sectors of the economy. No specific sectors are named in the title, and the bill text is not provided, but the focus is on antitrust monitoring.

The bill authorizes no funding and does not mandate any enforcement action. It is purely a study-and-report mechanism. Without appropriations or a directive to act, the working group's findings would be informational only. Actual antitrust enforcement remains with existing agencies and laws.

There are no related signals, procurement actions, or presidential actions converging with this bill. It stands alone as a procedural measure with no immediate market implications.

No publicly traded companies are directly affected. The bill does not alter any company's revenue, costs, or competitive landscape. Structural winners or losers cannot be identified at this stage.

The legislative path is long: the bill must pass the House Judiciary Committee, the full House, the Senate, and be signed by the President. With a junior sponsor and no cosponsors, momentum is low. The 119th Congress runs through 2027, but early-stage study bills rarely advance without broader support.

Key Legislators

Rep. Vindman, Eugene Simon [D-VA-7]

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderOct 22, 2026

DECREASING HOUSING COSTS FOR THE AMERICAN PEOPLE

This executive order directs the Federal Housing Finance Agency to create pilot programs for automatic cancellation of mortgage insurance when borrowers have sufficient equity, and to expand a title insurance pilot to reduce costs for refinancing. It establishes a task force to promote manufactured housing by standardizing permits and reducing regulatory barriers. It also orders the Departments of Agriculture and Veterans Affairs to reduce interest rates on direct home loans.

proclamationOct 22, 2026

Adjusting Imports of Wind Turbines and Their Parts and Components into the United States

This proclamation initiates negotiations to adjust imports of wind turbines and their components under Section 232, citing national security concerns including cybersecurity vulnerabilities, radar interference, and grid reliability. It does not immediately impose tariffs but sets the stage for potential trade restrictions, and notes that certain wind turbine components made of aluminum, steel, or copper are already subject to existing tariffs.

Exec OrderOct 19, 2026

Advancing Women's Health to Improve Outcomes in All Phases of Life

This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.

Free — no credit card

Get the next market-moving signal before the news does

HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.

Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.

Free forever plan · No credit card · Unsubscribe in one click

Want the live terminal too? Create a free account →